Alt image -https://content.stockstotrade.com/wp-content/uploads/2026/10/bicara-therapeutics-falls-40.webp

Bicara Therapeutics Falls 45% Today

TIM BOHEN•UPDATED OCT. 28, 2026, 3:15 PM ET
Reviewed by Ben Sturgilland Fact-checked by Jeff Zananiri

Bicara Therapeutics fell 45%, but no company news or filing explains the sharp decline.

BCAX Candlestick Chart

Get Free Alerts

Why Bicara Therapeutics Stock Fell Today

Bicara Therapeutics Inc. (NASDAQ: BCAX) fell 45% to $9.68 this afternoon, after closing at $17.48 in the prior session. No company news or filing explains the decline, so the reason for the selloff remains unclear. The move came with unusually active trading, but trading activity alone does not show what prompted sellers to act.

What Bicara Therapeutics Inc. Does

Bicara is a clinical-stage drug developer, meaning its treatments are still being tested in people and are not established products for sale. Its lead program, Ficerafusp Alfa, is being developed for solid tumors, cancers that form masses in body tissue. Because the treatment is still in development, progress in testing matters to the company’s future prospects.

Bicara’s Early Trading Range

Shares reached a high in the mid $17s in premarket trading, before regular trading began, and later reached the high $9s. This wide move shows how sharply the stock repriced during the session, but it does not identify a company-specific trigger.

Bicara Trading Volume Today

Trading totaled about 12 million shares, showing unusually active trading during the session. That figure counts shares changing hands, not separate investors buying or selling. The same share can trade more than once as buyers and sellers agree on new prices.

Quick Financial Overview

Bicara is a small-cap, meaning its total stock-market value is modest, at $640.6M. It reported $497.3M in cash, cash equivalents, and short-term investments as of June 30, 2026, a mix of money on hand and investments it can access or sell soon. That cash is estimated to cover about thirty-four months at the recent spending rate; a cash runway is an estimate, not a promise.

Bicara Operating Cash Use and Net Loss

Bicara used $44.2M in operating cash, meaning money spent on its ongoing work, and reported a net loss of $55.4M. The net loss compares income with expenses, while operating cash use tracks money leaving the business. The runway estimate uses that quarter’s spending rate, which can change as the company runs its drug studies and other operations.

Get Free Alerts

Bicara Stock Is down 51% Over Six Months

Bicara has been trending lower, with shares down 43.64% over the past month. Today’s move was the biggest daily move in the last year, accelerating that existing decline rather than starting a new slide. The longer drop matters because a sharp daily move now follows sustained weakness, not a rising chart.

Bicara Next Earnings Report

The next listed earnings report is Monday, consensus $-0.84. Consensus means the average estimate from analysts who follow the company. The report can update holders on operating costs and whether Bicara’s cash is supporting its work at the recent pace.

Get Free Alerts

Conclusion

Bicara’s reported cash position covers the wait, giving the company time to keep developing its lead treatment. Its next earnings report can show whether spending remains near the recent pace; steadier spending would support that cushion, while faster cash use would shorten it.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.


The Game is Rigged

But Our AI-driven analysis Has Leveled the Playing Field

Sign up for access to institutional grade tools and insights – and join 10,000+ traders